Acadia Pharmaceuticals received a negative trend vote from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on February 2, 2026, for its marketing‑authorization application for trofinetide, the company’s treatment for Rett syndrome. The CHMP decision, issued after an oral briefing on January 27, 2026, states that the application will not be adopted in its current form and that Acadia may request a re‑examination within the 15‑day window permitted by EU regulations.
The CHMP cited concerns about the clinical data presented, noting that the evidence of benefit was insufficient and that safety questions remained unresolved. While the committee did not provide a detailed list of deficiencies, the negative trend vote signals that the agency requires additional data or a revised submission before it can consider approval. Acadia has indicated it will submit a revised application and will seek a re‑examination to address the committee’s concerns.
The potential impact on Acadia’s commercial prospects is significant. A successful EU launch could add an estimated $200‑$300 million in annual revenue at U.S. pricing levels, reflecting the size of the Rett syndrome market in Europe and the high cost of the drug. The negative vote therefore represents a headwind that could delay market entry by several months and reduce the company’s ability to capture this revenue stream.
Acadia’s financial position remains strong. For 2025, the company guided total revenue of $1.070 billion to $1.095 billion, driven by sales of NUPLAZID and DAYBUE in the United States. Cash, cash equivalents, and investment securities stood at $847 million as of September 30, 2025, giving Acadia a robust balance sheet to weather the regulatory setback and fund ongoing development.
CEO Catherine Owen Adams expressed disappointment with the CHMP outcome but reiterated confidence in trofinetide’s efficacy and the company’s commitment to securing EU approval. She emphasized that Acadia will work closely with regulators to address the identified gaps and that the company remains focused on expanding access to patients worldwide.
Analysts have maintained their positive outlook on Acadia, citing the company’s strong U.S. commercial performance, solid cash position, and the potential for a successful re‑examination. The negative CHMP vote is viewed as a temporary setback rather than a long‑term threat to the company’s growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.